Robotic Pelvic and Retroperitoneal Lymph Node Dissection
Pelvic lymph node dissection (PLND) and retroperitoneal lymph node dissection (RPLND) remain critical components of many urologic disease processes and procedures. Dissection may provide accurate lymph node staging and confer potential therapeutic benefit. For prostate cancer management, lymph node dissection at prostatectomy provides an opportunity for staging and, when compared with other treatment options, has been shown to have a possible therapeutic benefit by lower cancer-specific death rates [1–3]. In the management of testicular cancer, RPLND is considered an established treatment option, depending on the histologic subtype and clinical stage of the disease. The robotic platform allows for a full therapeutic dissection with equivalent oncologic outcomes and shorter convalescence when compared with open RPLND [4, 5]. Finally, in the management of patients with locally advanced renal masses (T3–T4) or unfavorable clinical and/or pathologic features, a template lymph node dissection may offer improved survival [6–8].
KeywordsProstate cancer Renal cell carcinoma Upper tract urothelial carcinoma Testicular cancer Nonseminomatous germ cell tumor Seminoma Pelvic lymph node dissection PLND Retroperitoneal lymph node dissection RPLND
- 5.National Comprehensive Cancer Network. Testicular cancer. (Version 2. 2016).Google Scholar
- 12.Nicolai N, MIceli R, Artusi R, Piva L, Pizzocaro G, Salvioni R. A simple model for predicting nodal metastasis in patients with clinical stage 1 nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol. 2004;171:172–6.CrossRefPubMedCentralGoogle Scholar
- 13.Weissbach L, Bussar-Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol. 2000;37:582–94.CrossRefPubMedCentralGoogle Scholar